Zimmer Biomet Holdings (NYSE:ZBH) has declared a quarterly dividend of $0.24 per share for the second quarter of 2025, despite lowering its 2025 profit forecast amid tariff uncertainties. Kevin Thornal has been appointed Group President and is predicted to oversee a potential 17.25% upside in the healthcare sector. Additionally, Zimmer Biomet has completed the acquisition of Paragon 28, allowing it to tap into the high-growth Ambulatory Surgical Centre expansion. However, with lowered price targets due to disappointing Q1 results, the stock has been affected negatively. Analysts suggest the company's stock may be undervalued by 39%, owing to its strong cash flow outlook and continued growth through acquisitions and innovations amid macroeconomic issues. Despite this, Zimmer Biomet was seen as underperforming when compared to competitors and some of its products have been granted regulatory approvals, indicating potential for growth and expansion.
Zimmer Biomet Holdings ZBH News Analytics from Thu, 05 Sep 2024 07:00:00 GMT to Fri, 30 May 2025 17:35:37 GMT -
Rating -5
- Innovation 0
- Information 4
- Rumor -2
